Immuneering Co. (NASDAQ:IMRX) Short Interest Update

Immuneering Co. (NASDAQ:IMRX) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,740,000 shares, a drop of 19.4% from the January 31st total of 2,160,000 shares. Currently, 7.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,880,000 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On Immuneering

Several institutional investors have recently modified their holdings of IMRX. Corsair Capital Management L.P. purchased a new stake in Immuneering during the 3rd quarter valued at $25,000. Tang Capital Management LLC purchased a new stake in shares of Immuneering in the fourth quarter valued at $27,000. Marshall Wace LLP bought a new stake in shares of Immuneering in the 4th quarter worth about $47,000. First Manhattan CO. LLC. purchased a new position in shares of Immuneering during the 4th quarter worth about $71,000. Finally, XTX Topco Ltd boosted its stake in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after purchasing an additional 20,871 shares during the period. 67.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IMRX shares. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price objective on shares of Immuneering in a research report on Thursday, February 6th. Chardan Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Immuneering in a research report on Wednesday, January 8th. Finally, Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Immuneering presently has an average rating of “Hold” and an average target price of $12.20.

Immuneering Price Performance

Shares of NASDAQ IMRX traded up $0.01 during mid-day trading on Tuesday, hitting $1.49. 222,637 shares of the company’s stock traded hands, compared to its average volume of 2,522,579. The company has a market capitalization of $46.11 million, a P/E ratio of -0.75 and a beta of -0.36. Immuneering has a 1 year low of $1.00 and a 1 year high of $6.78. The company’s 50-day moving average is $1.97 and its two-hundred day moving average is $1.95.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.